Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 9;8(9):946.
doi: 10.3390/jof8090946.

The Changing Landscape of Invasive Fungal Infections in ICUs: A Need for Risk Stratification to Better Target Antifungal Drugs and the Threat of Resistance

Julien Poissy  1 , Anahita Rouzé  1 , Marjorie Cornu  2 , Saad Nseir  1 , Boualem Sendid  2
Affiliations
Review

The Changing Landscape of Invasive Fungal Infections in ICUs: A Need for Risk Stratification to Better Target Antifungal Drugs and the Threat of Resistance

Julien Poissy et al. J Fungi (Basel). .

Abstract

The landscape of invasive candidiasis and invasive aspergillosis has changed dramatically in intensive care units over the past two decades. Today, we are faced with new risk factors such as the emergence of resistance, but are also equipped with new therapeutic strategies and diagnostic tools which are changing epidemiological data and diagnostic algorithms. Some common points need to be addressed: (i) the best way to use microbiological tools and to integrate their results in decisional algorithms; (ii) the need to find the optimum balance between under-diagnosis and overtreatment; (iii) and the need to decipher pathophysiology. In this short review, we will try to illustrate these points.

Keywords: antifungal; candidemia; diagnosis algorithm; invasive aspergillosis; invasive candidiasis; risk factors.

PubMed Disclaimer

Conflict of interest statement

J.P. has received fees for lectures from Giled; A.R. has received fees for lecture from MSD; M.C. has received fees for lectures from Pfizer; S.N. has received payment for lectures from MSD, Pfizer, Gilead, Biomérieux, Bio Rad, and Fischer and Paykel; B.S. has received research grants from Gilead, Biomérieux and Lesaffre international.

Figures

Figure 1
Figure 1
The spectrum of invasive candidiasis.
See this image and copyright information in PMC

References

    1. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 2004;39:309–317. doi: 10.1086/421946. - DOI - PubMed
    1. Lamoth F., Lockhart S.R., Berkow E.L., Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J. Antimicrob. Chemother. 2018;73:i4–i13. doi: 10.1093/jac/dkx444. - DOI - PMC - PubMed
    1. Chapman B., Slavin M., Marriott D., Halliday C., Kidd S., Arthur I., Bak N., Heath C.H., Kennedy K., Morrissey C.O., et al. Changing epidemiology of candidaemia in Australia. J. Antimicrob. Chemother. 2017;72:1103–1108. doi: 10.1093/jac/dkx047. - DOI - PubMed
    1. Bassetti M., Giacobbe D.R., Vena A., Trucchi C., Ansaldi F., Antonelli M., Adamkova V., Alicino C., Almyroudi M.P., Atchade E., et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: Results of the EUCANDICU project. Crit. Care. 2019;23:219. doi: 10.1186/s13054-019-2497-3. - DOI - PMC - PubMed
    1. Kett D.H., Azoulay E., Echeverria P.M., Vincent J.L. Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study. Crit. Care Med. 2011;39:665–670. doi: 10.1097/CCM.0b013e318206c1ca. - DOI - PubMed

LinkOut - more resources